帕金森病患者的4米步行测试:可靠性和有效性研究
Taskin Ozkan1, Fatih Soke2, Nigar Esra Erkoc Ataoglu3
1Giresun University, Vocational School of Health Services, Therapy and Rehabilitation, Giresun, Turkey.
Gait & posture
|March 6, 2025
概括
4米步行测试 (4-MWT) 可靠地测量了帕金森病患者的行走能力. 它在评估疾病进展和治疗有效性方面显示出出色的有效性.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 显著影响着人的流动性和生活质量.
- 客观措施对于跟踪PD进展和治疗疗效至关重要.
- 步行评估对于了解PD的功能限制至关重要.
研究的目的:
- 为了评估4米步行测试 (4-MWT) 的测试-重新测试可靠性.
- 为了确定4-MWT的最小可检测变化 (MDC).
- 评估4MWT在患有帕金森病 (PwPD) 的患者中的并发和已知组有效性.
主要方法:
- 42名PwPD和33名健康对照参与.
- 类内相关系数 (ICC) 和MDC量化可靠性.
- 通过与已建立的步态和PD尺度 (10-MWT,DGI,TUG,FOG-Q,H&Y,MDS-UPDRS) 的相关性来评估有效性.
- 在PwPD中,跌落者与非跌落者之间的4MWT时间的比较.
主要成果:
- 4-MWT的测试-重新测试可靠性非常好 (ICC = 0.957).
- 最小可检测变化 (MDC) 确定在0.14 m/s.
- 在4-MWT与其他措施之间观察到相当至极好的相关性 (r = -0.428至0.937,p <0.05).
- 在4MWT的表现中,落者和非落者之间存在显著的差异 (p < 0.05).
结论:
- 4-MWT证明了PwPD的卓越可靠性和有效性.
- 它是评估在有限空间行走的实用工具.
- 4-MWT可以有效地监测PD进展和治疗反应.
相关概念视频
Parkinson's Disease: Treatment
178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
Parkinson's Disease: Overview
415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415


